Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-κB expression in the kidneys of diabetic rats

National Medical Journal of China

Volumn 88, Issue 8, 2008, Pages 540-545

  Chen, Bing ^a   Zhang, Yan ^b   Liu, Gang ^b   Guan, Guang Ju ^b   Hou, Xiang Hua ^b   Li, Xue Gang ^b   Liu, Jun Li ^b  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b NONE

Author keywords

Diabetic nephropathies; Mycophenolic acid; NF kappaB; Tumor necrosis factor

Indexed keywords

ALBUMIN; CITRIC ACID; CREATININE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITROGEN; STREPTOZOCIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UREA; VALSARTAN;

ABDOMINAL AORTA; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLOMERULUS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY FUNCTION; KIDNEY TUBULE; LIVER HYPERTROPHY; MACROPHAGE; MALE; NEPHRECTOMY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN URINE LEVEL; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES; UPREGULATION; UREA NITROGEN BLOOD LEVEL; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; MYCOPHENOLIC ACID; NF-KAPPA B; RANDOM ALLOCATION; RATS; RATS, WISTAR; TETRAZOLES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME; VALINE;

EID: 43649094617     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kumar D, Zimpelmann J, Robertson S, et al. Tubular and interstitial cell apoptosis in the streptozotocin-diabetic rat kidney. Nephron Exp Nephrol,2004,96:e77-88.
2. Kumar D, Robertson S, Burns KD. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem,2004,259(1-2):67-70.
3. Murata I, Takemura G, Asano K, et al. Apoptotic cell loss following cell proliferation in renal glomerui of Otsuka Long-Evans Tokushima Fatty rats, a model of human type 2 diabetes. Am J Nephrol,2002,22(5-6):587-595.
4. Kelly DJ, Stein-Oakley A, Zhang Y, et al. Fas-induced apoptosis is a feature of progressive diabetic nephropathy in transgenic (mRen-2) 27 rats: attenuation with renin-angiotensin blockade. Nephrology(Carlton),2004,9:7-13.
5. Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int,2003,63:209-216.
6. Chinese source.
7. Wu YG, Lin H, Qi XM, et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol,2006,6:445-453.
8. Chinese source.
9. Chinese source.
10. Zhang Y, Chen B, Hou XH, et al. Effect of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy. Chin Med J (Engl),2007,120:988-995.
11. Mi QS, Ly D, Lamhamedi-Cherradi SE, et al. Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes,2003,52:1967-1975.
12. Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, et al. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol,2003,4:255-260.
13. Al-Douahji M, Brugarolas J, Brown PA, et al. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int,1999,56:1691-1699.
14. Fan YP, Weiss RH. Exogenous attenuation of p21 (Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol,2004,15:575-584.
15. Baba M, Wada J, Eguchi J, et al. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms. J Am Soc Nephrol,2005,16:3222-3234.
16. Xu SQ, El-Deiry WS. p2l (WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun,2000,269:179-190.
17. Wajant H. TRAIL, and NF-kappaB signaling-a complex relationship. Vitam Horm,2004,67:101-132.
18. Aggarwal BB, Bhardwaj U, Takada Y. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm,2004,67:453-483.
19. Mezzano S, Aros C, Droguett A, et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant,2004,19:2505-2512.
20. Chinese source.
21. Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endotheial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res,2005,70:137-141.
22. Wu X, Zha D, Xiang G, et al. Combined MMF and insulin therapy prevents renal injury in experimental diabetic rats. Cytokine,2006,36:229-236.